Skip to main content
SpringerLink
Log in

Management of post-menopausal osteoporosis: Something new on the horizon?

  • Opinion
  • Published:
Journal of Endocrinological Investigation Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Consensus development conference. Diagnosis, prophyaxis, and treatment of osteoporosis. Am. J. Med. 1993, 94: 646–650.

    Article  Google Scholar 

  2. Faulkner K.G. Bone matters. Are density increases necessary to reduce fracture risks? J. Bone Miner. Res. 2000, 15: 183–187.

    Article  PubMed  CAS  Google Scholar 

  3. Guyatt G.H. Evidence-based management of patients with osteoporosis. J. Clin. Densitom. 1998, 1: 395–402.

    Article  PubMed  CAS  Google Scholar 

  4. Grady D., Herrington D., Bittner V., et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy. Heart and estrogen/progestin replacement study follow-up (HERS II). JAMA 2002, 288: 49–57.

    Article  PubMed  Google Scholar 

  5. Mashiba T., Turner C.H., Hirano T., Forwood M.R., Johnston C.C, Burr D.B. Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles. Bone 2001, 28: 524–531.

    Article  PubMed  CAS  Google Scholar 

  6. Schnitzer T., Bone H.G., Crepaldi G., et al. Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Aging Clin. Exp. Res. 2000, 12: 1–12.

    Article  CAS  Google Scholar 

  7. Reid I.R., Brown J.P., Burckhardt P., et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N. Engl. J. Med. 2002, 346: 653–661.

    Article  PubMed  CAS  Google Scholar 

  8. Adami S., Delmas P., Felsenberg D., et al. Three-monthly 2 mg intravenous ibandronate bolus injections significantly increase bone mineral density in women with postmenopausal osteoporosis. Osteoporos. Int. 2002, 13: S14.

    Google Scholar 

  9. Lindsay R., Cosman F., Lobo R.A., et al. Addition of alendronate to ongoing hormone replacement therapy in the treatment of osteoporosis: A randomized, controlled clinical trial. J. Clin. Endocrinol. Metab. 1999, 84: 3076–3081.

    PubMed  CAS  Google Scholar 

  10. Johnell O., Scheele W.H., Reginster J.Y., Need A.G., Seeman E. Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis. J. Clin. Endocrinol. Metab. 2002, 87: 985–992.

    Article  PubMed  CAS  Google Scholar 

  11. Harris S.T., Eriksen E.F., Davidson M., et al. Effect of combined risedronate and hormone replacement therapies on bone mineral density in postmenopausal women. J. Clin. Endocrinol. Metab. 2001, 86: 1890–1897.

    PubMed  CAS  Google Scholar 

  12. Neer R.M., Arnaud CD., Zanchetta J.R., et al. Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N. Engl. J. Med. 2001, 344:1434–1441.

    Article  PubMed  CAS  Google Scholar 

  13. Meunier P.J., Slosman D.O., Delmas P.D., et al. Strontium ranelate: Dose-dependent effects in established postmenopausal vertebral osteoporosis-A 2-year randomized placebo controlled trial. J. Clin. Endocrinol. Metab. 2002, 87: 2060–2066.

    PubMed  CAS  Google Scholar 

  14. Meunier P.J., Roux C., Ortolani S., et al. Strontium ranelate reduces the vertebral fracture risk in women with postmenopausal osteoporosis. Osteoporos. Int. 2002, 13: O45.

    Google Scholar 

  15. Hochberg M.C., Greenspan S., Wasnich R.D., Miller P., Thompson D.E., Ross P.D. Changes in bone density and turnover explain the reductions in incidence of nonvertebra fractures that occur during treatment with antiresorptive agents. J. Clin. Endocrinol. Metab. 2002, 87:1586–1592.

    Article  PubMed  CAS  Google Scholar 

  16. Lips P. Vitamin D deficiency and secondary hyperparathyroidism in the elderly: Consequences for bone loss and fractures and therapeutic implications. Endocr. Rev. 2001, 22: 477–501.

    Article  PubMed  CAS  Google Scholar 

  17. Rittmaster R.S., Bolognese M., Ettinger M.P. et al. Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate. J. Clin. Endocrinol. Metab. 2000, 85: 2129–2134.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, University of Florence, Viale Pieraccini 6, 50139, Florence, Italy

    Maria Luisa Brandi

Authors
  1. Maria Luisa Brandi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Maria Luisa Brandi.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Brandi, M.L. Management of post-menopausal osteoporosis: Something new on the horizon?. J Endocrinol Invest 26, 170–173 (2003). https://doi.org/10.1007/BF03345147

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03345147

Key-words

Search

Navigation